Some clarification neededBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3589 (Published 07 July 2010) Cite this as: BMJ 2010;341:c3589
- Richard G Richards, assistant director of public health1
- 1NHS Derbyshire County, Babington Hospital, Belper, Derbyshire DE56 1WH
With reference to the use of interferon beta in multiple sclerosis,1 Betaferon is already off patent, and there has been an unholy scramble to get access to production facilities.2 Extavia is not a generic or biosimilar drug but simply another branded version of interferon beta-1b made in the same factory. It cost …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial